Series B financing round of SQ Innovation

SQ Innovation AG, a life-science company developing innovative solutions for the treatment of worsening heart failure, announced the closing of its Series B financing. This financing round provides the capital necessary for the U.S. commercial launch of Lasix® ONYU, a prescription drug-device combination that treats edema caused by fluid build-up for adult patients with chronic heart failure, which was approved by the FDA on October 7, 2025. The round was led by Mr. van der Poel with further participation of new and existing shareholders.

Lenz & Staehelin advised SQ Innovation. The team included Simone Ehrsam, Tino Gaberthüel, Nicolas Lehmann, Raphael Fries and Lucas Gericke (all Corporate and M&A) and Peter Ling (IP).